e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Inflammation and remodelling in lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Elena Lopez Rodriguez (Hannover, Germany), Carolin Laukamp, Alberto Hidalgo, Antonio Cruz, Jesus Perez-Gil, Matthias Ochs, Lars Knudsen, Elena Lopez-Rodriguez
Source:
International Congress 2015 – Inflammation and remodelling in lung disease
Session:
Inflammation and remodelling in lung disease
Session type:
Thematic Poster Session
Number:
3910
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Elena Lopez Rodriguez (Hannover, Germany), Carolin Laukamp, Alberto Hidalgo, Antonio Cruz, Jesus Perez-Gil, Matthias Ochs, Lars Knudsen, Elena Lopez-Rodriguez. New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung. Eur Respir J 2015; 46: Suppl. 59, 3910
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Risk factors associated with the development of interstitial lung abnormalities
Surfactant protein expression at various COPD Gold stages
Dexamethasone inhibits secretory and cytosolic phospholipases A2 in alveolar macrophages in acute lung injury
Related content which might interest you:
Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2014 – ILDs 1
Year: 2014
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
Source: International Congress 2014 – ILDs 4
Year: 2014
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 39: 359-365
Year: 2012
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Lung transplantation in idiopathic pulmonary fibrosis
Source: International Congress 2016 – Russia Session
Year: 2016
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
The impact of emphysema in pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 153-157
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept